

Enumeral Biomedical Holdings, Inc.  
 Form 3  
 April 03, 2015

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â HARRIS & HARRIS GROUP INC /NY/		(Month/Day/Year)	Enumeral Biomedical Holdings, Inc. [ENUM]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	
1450 BROADWAY,Â 24TH FLOOR			(Check all applicable)	
(Street)			<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below)    (specify below)	
NEW YORK,Â NYÂ 10018			5. If Amendment, Date Original Filed(Month/Day/Year)	
(City)	(State)	(Zip)	6. Individual or Joint/Group Filing(Check Applicable Line)	
			<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,966,368	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
---	---	--	---	---	--

Edgar Filing: Enumeral Biomedical Holdings, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	08/04/2014	08/03/2024	Common Stock	20,000	\$ 1	I	Daniel Wolfe
Stock Option (Right to Buy)	Â (1)	08/03/2024	Common Stock	60,000	\$ 1	I	Daniel Wolfe
Common Stock Purchase Warrant (2)	07/31/2014	02/02/2024	Common Stock	255,120	\$ 0.2451	D	Â
Common Stock Purchase Warrant	07/31/2014	07/30/2019	Common Stock	1,500,000	\$ 2	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HARRIS & HARRIS GROUP INC /NY/ 1450 BROADWAY 24TH FLOOR NEW YORK, NY 10018	Â	Â X	Â	Â

## Signatures

/s/ Daniel Wolfe,  
President

04/03/2015

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option vests and becomes exercisable as follows: (a) 36,667 shares were vested as of August 4, 2014, and (b) 23,333 will vest in 14
- (1) equal monthly installments through October 1, 2015. The option has been issued to Daniel Wolfe, a director of the Issuer. Mr. Wolfe has assigned the economic benefit of the option to the reporting person.
  - (2) Represents a warrant issued to the reporting person in exchange for a warrant previously issued by Enumeral Biomedical Corp. (the "Predecessor") pursuant to the terms of the merger of the Predecessor with a wholly-owned subsidiary of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.